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A Novel Recessive Connexin 31 (GJB3) Mutation in a Case of
Erythrokeratodermia Variabilis
To the Editor:
Erythrokeratodermia variabilis (EKV, MIM 133200) is part
of the clinically and genetically heterogeneous group of
erythrokeratodermias. It is characterized by migrating red
patches resembling a geographic map, and by localized or
generalized hyperkeratosis with scaling of the skin. The
hyperkeratotic areas often show well-demarcated, geogra-
phically outlined, and fixed plaques, in a strikingly symme-
trical distribution. Scales on the skin vary in appearance,
from fine and yellow to thick and brown, leading to a hystrix-
like appearance. The erythematous patches seem to occur
independently from the hyperkeratosis. In some cases,
the patients also show non-epidermolytic palmo-plantar
keratoderma. The study was conducted according to the
Declaration of Helsinki guidelines. We also obtained patient
consent to use biopsy and blood samples for genetic
analysis.
The hyperkeratosis and erythema can be triggered by
stress, such as temperature changes, mechanical irritation,
or sun exposure. The onset is usually at birth or during
infancy, and the disease persists throughout life. EKV is
mainly inherited as an autosomal dominant disease,
although recessive transmission has occasionally been
reported (Gottfried et al, 2002). Mutations associated with
EKV have been identified in connexin (Cx) genes, Cx31 and
30.3 (Richard et al, 1998, 2000, 2003; Wilgoss et al, 1999;
Macari et al, 2000).
Cxs are a group of proteins that share a common pattern
of structural motifs or domains, including four trans-
membrane domains (M1–4), two extracellular domains
(E1–2), and three cytoplasmic domains. The cytoplasmic
domains are the amino-terminus (NT), the cytoplasmic loop
(CL), and the carboxy-terminus (CT). The CL and CT domains
are characteristic of each connexin, while the membrane
spanning and the extracellular domains are highly con-
served.
Homomeric or heteromeric interaction of six Cxs leads to
the formation of the connexon or hemichannel (Kumar and
Silula, 1996), localized on the plasma membrane surface.
The extracellular interaction of two opposing connexons
generates a channel. The clustering of a large number of
channels forms the gap junction (Yeager et al, 1996).
Gap junctional channels show selective permeability and
voltage sensitivity (Bruzzone et al, 1996; Goodenough et al,
1996; Kumar and Giulia, 1996). They play a role in the
response to environmental stimuli in almost all cells of
multicellular organisms. The coordinated exchange of mole-
cules is used in a wide spectrum of cellular activities,
such as transmission of neuronal signals, cell contraction,
cell growth control, organ homeostasis, and differentiation
(Goodenough et al, 1996; White and Paul, 1999). Reflecting
their communicating functions, Cxs are expressed in a wide
variety of tissues (Krutovskikh and Yamasaki, 2000).
Eleven human Cx genes have been described, several
of which have been associated with diseases such as
Charcot–Marie–Tooth (GJB1, MIM #304040), hearing loss
(GJB2, GJB3, and GJB6; MIM #121011 and 603324),
cataract (GJA3 and GJA8; MIM #121015 and #600897),
EKV (GJB3, GJB4), a variant of Vohwinkel syndrome (GJB2,
MIM #148350), KID syndrome (GJB2, MIM #148210), and
Oculodentodigital dysplasia (MIM #164200).
We examined a 16-y-old female presenting hyperker-
atosis of palms and soles (Fig 1a,b), diffuse erythematous
patches of body skin, changing in size and shape (Fig 1d),
and a diffuse ichthyotic hyperkeratosis, characterized by
thick dark brown scales (Fig 1a), sparing only small areas of
the body. The patient’s parents reported the presence of
erythema localized only on the limbs at birth, which disa-
ppeared within 1 wk. The erythematous lesions reappeared
at 1 mo of age, extended to the entire skin surface, and they
were changing location over the span of a day. During the
first decade of life, the erythema decreased in intensity,
while the diffusion of hyperkeratotic areas increased. The
other family members were not affected by the disease, nor
by any other dermatological pathology. The histological
examination (Fig 1c) showed ortho-hyperkeratosis, papillo-
matosis, and light superficial lymphocyte infiltration in the
dermis. Audiometric analysis of the proband and her
parents did not reveal hearing impairment.
As mutations in GJB3 and GJB4 genes have been
correlated to EKV, we investigated for mutations in these
two genes. We obtained the consensus for skin biopsy and
genetic analysis from patient and parents. Amplification and
sequence analysis of the Cx31 gene (amplified from RNA
extracted from patient palmar epidermis) revealed a novel
homozygous mutation, a G to A transversion at base pair
829 (according to Genebank sequence AF099730). The
mutation leads to the substitution of a conserved glutamic
acid in position 100 (ConSurf analysis in Gottfried et al, 2002
ConSurf, University of Tel Aviv, Israel), localized in the CL
domain of the protein, with a lysine (Fig 2b). The complete
analysis of the Cx31 and Cx30.3 coding region did not show
any other mutation. Sequence analysis of PCR fragments
amplified from genomic DNA of other family members
showed the presence of the mutated allele, in heterozyg-
osity (Fig 2c), in both parents and in other unaffectedAbbreviations: Cx, connexin; EKV, erythrokeratodermia variabilis
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Figure 1
Clinical presentation and histopathology.
(a) Diffuse ichthyotic hyperkeratosis, charac-
terized by thick dark brown scales and
erythematous patches of body skin, changing
in size and shape in the course of weeks,
leaving some areas completely unaffected. (b)
Hyperkeratosis of palms. (c) Hematoxylin–
eosin staining of patient skin sections, show-
ing orthohyperkeratosis, papillomatosis and
light superficial dermal lymphocytic infiltra-
tion. (d) Clinical presentation of the patient
after Acitretin treatment. The dark brown
scales have almost disappeared, while er-
ythematous patches are still present.
Figure 2
Pedigree, mutation analysis and enzymatic digestion for confirmation analysis. (a) Pedigree of the patient’s maternal and paternal family shows
the presence of a common ancestor. Asterisks indicate the individuals for whom the DNA was available for mutational analysis. (b–d) Sequence
analysis of the Cx31 gene, performed on patient cDNA (RT-PCR) and genomic DNA (PCR) and only on genomic DNA (PCR) for all the other
members. The primers used are ACTCAGAACACTGCCTGGTACATA (þ ) and GGCACTGGGCCTGTGGGTTAC (), designed from the published
sequence (AF099030). Wild-type guanine 829 is represented by a single black peak in the chromatogram (black arrow in panel d). The green peak at
position 829 indicates a Timine residue (black arrow in panel b), which leads to the amino acid substitution Glu100Lys. In panel c, the presence of
two peaks (black/green indicated by the arrow) reveals the presence of both alleles in heterozygous individuals. (e) The G to A transversion ablates
an existing BseR-I restriction site. The digestion with this enzyme of the 1117 bp amplicon produces two bands (703 bp, 414 bp, lane 7) for the wild-
type allele, three bands in the presence of the heterozygous mutation (1117 bp, 703 bp, 414 bp, lanes 1–2–4–5–6–8) and one band when both alleles
are mutated (1117 bp, lane 3). The results indicate that the patient’s parents and most other relatives (with one exception) are heterozygous for the
mutation.
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members of the family. The mutation deletes a BseR-I
restriction site; therefore, restriction analysis has been used
to confirm the mutation and to exclude polymorphisms. We
generated a 1117 bp PCR amplicon normally containing the
enzyme recognition site, which upon digestion resulted in
two bands. The patient homozygous for the mutation
showed only an uncut band of 1117 bp (Fig 2e). The
patient’s parents were heterozygous, suggesting that the
mutation has been inherited from a common ancestor
(Fig 2a).
The patient was treated for 2 mo with a 20 mg daily dose
of Acitretin (retinoic acid derivative, Graham-Brown and
Chave, 2002), and showed almost complete remission of hy-
perkeratotic phenotype, without improvement of the
erythema (Fig 1d). The effect on the hyperkeratosis might
be due to the downregulation of the mutated gene by
retinoic acid, since we (unpublished data) and others
(Grummer et al 1996) have shown the ability of retinoic
acid to downregulate Cx genes. Functional studies on Cxs
mutations (Di et al, 2002; Gottfried et al, 2002) demon-
strated an accumulation in the cytoplasm of the mutant
proteins, suggesting that they cannot be properly trans-
ported to the plasma membrane, probably due to defective
folding, hemichannel assembly or membrane targeting.
Moreover, induction of cell death mediated by the mutated
Cx31 has been reported (Diestel et al, 2002). It has also
been shown that Cx31 mutations affect calcium metabolism
(Rouan et al, 2003). Cx31 is also expressed in peripheral
and auditory nerves, and mutations causing dominant
(Xia et al, 1998) and recessive (Liu et al, 2000) hearing
impairment and neuropathies have been described (Lopez-
Bigas et al, 2001). Since the patient studied showed only
dermatologic symptoms, we can conclude that the amino
acid substitution and the specific domain affected by the
mutation play an important role in determining the clinical
phenotype, confirming that mutations involving different
regions of these proteins give rise to different diseases.
The data reported clearly indicate that the homozygous
expression of the E100K mutation is responsible for the EKV
phenotype, by a loss of function mechanism rather than a
dominant-negative one, described in the majority of Cx31
mutations. Further studies on connexin gene mutations will
help to define their biochemical and physiological role in
tissues where they are expressed.
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